title: Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.
abstract: Recent work in genetics has identified essential driver mutations in gliomas and has profoundly changed our understanding of tumorigenesis. New insights into the molecular basis of glioma has informed the development of therapies demonstrating considerable potential, including immunotherapeutic approaches such as peptide and dendritic cell vaccines against EGFRvIII. However, the selective targeting of one component of a dysregulated pathway may be inadequate for a durable clinical response, given the intratumoral heterogeneity of glioblastoma (GBM) and hypermutated profiles displayed by tumor recurrences. Immune checkpoint blockade with anti-cytotoxic T lymphocyte antigen-4 (CTLA) and anti-programmed cell death 1 (PD-1) have demonstrated encouraging results in clinical trials with other solid tumors, and recent data suggest that this type of therapy may be particularly useful for tumors with high mutational burdens. Although the survival for patients with GBM has remains grim, the use of immunotherapy may finally change patient outcomes.
authors.affiliation: Department of Neurosurgery, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 118, Baltimore, MD, 21287, USA.
authors.forename: Joanna Y
authors.initials: JY
authors.lastname: Wang
authors.forename: Chetan
authors.initials: C
authors.lastname: Bettegowda
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy; D019468:Disease Management; D005823:Genetics; D005910:Glioma / Q000235:genetics / Q000276:immunology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000145:classification / Q000379:methods* / Q000639:trends